Dermatology – Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials

 

Novartis announced the results from two pivotal, Phase III studies (SUNSHINE and SUNRISE), in which Cosentyx® (secukinumab) demonstrated rapid and sustained relief from the common clinical signs and symptoms of moderate-to-severe hidradenitis suppurativa (HS) with a favorable safety profile.
  • Results from two parallel trials show Cosentyx® (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa (HS) signs and symptoms
  • Safety results were consistent with the well-established Cosentyx safety profile
  • HS is a chronic, inflammatory skin condition affecting up to one in 100 people worldwide2, resulting in painful, potentially disfiguring lesions, which leaves feelings of stigmatization and can severely impact quality of life
  • Data from SUNSHINE and SUNRISE trials were submitted as part of regulatory applications to health authorities in Europe; plan to submit in the US by year end

Click here for the public data report 

Posted 26/10/2022


Join the HARMONIE Research Study to help us advance RSV protection in babies.

RSV is a common seasonal virus that infects nearly all babies by their second birthday. Most of the time it causes a mild illness, like a cold. However, for some babies, it leads to more severe lung problems such as bronchiolitis and pneumonia. RSV infection is unpredictable and is a leading cause of hospitalisations in babies. Most hospitalisations due to RSV occur in otherwise healthy babies, and it is difficult to know which babies will develop severe disease requiring medical care. More research is needed to protect babies from respiratory infections in the future.

About the HARMONIE Research Study

This HARMONIE Research Study is enrolling newborn babies to babies 12 months old. It follows on from other research studies which have been completed and is looking at how strongly babies can be protectedfrom serious illness due to RSV infection (respiratory syncytial virus) by giving them a single antibody dose.
The objective of the study is to further assess the impact of hospitalisations due to RSV.
As many as 28,860 babies in the UK, France, and Germany will take part in the study. With your consent, the study doctor will confirm if your baby can take part in the study based on your baby’s medical records.
To learn more about this study and whether it may be an option for your baby, please visit
RSVHarmonieStudy.com

 

for more HARMONIE News click here 

Posted 05/09/2022


UNDERSTANDING THE IMPACT HYPOGLYCAEMIA HAS ON PEOPLE LIVING WITH DIABETES

 

A team at the University of Sheffield recently completed some research on aspects of quality of life associated with hypoglycaemia for people living with diabetes.

They are now developing a questionnaire that could be used in future studies.

If you are interested in taking part, please click on the link to access the survey and find out more details about the research https://tinyurl.com/2s3k9a4k

 

 


Its #RED4RESEARCH Day 2022!

#Red4Research day aims to get as many people as possible wearing red to demonstrate their support and appreciation for all those participating, undertaking and supporting COVID-19 and other research.

On the front line and behind the scenes incredible research teams continue to collectively work on health and social care research. COVID-19 has forced us to do things differently, to be more innovative, flexible and more responsive. Over the past two years, the R&D community in collaboration with the health and care sectors and voluntary organisations has achieved a phenomenal amount.

Follow us on twitter @barnsleyrd with #red4research and see what is happening today.

Posted 17/06/2022


The Role of the Principal Investigator in Health and Social Care Research

https://twitter.com/BarnsleyRD/status/1537374931515744256

 

19th July 2022 12:00-13:00

The online event will clarify the role of a Principal Investigator (PI), allowing healthcare professionals to see research career progression.

The event is quite in its broad appeal and anyone who is interested in furthering their career in research should attend.

Nurses, Medical and Dental Staff, Midwives, Allied Health Professionals, Pharmacists, Healthcare Scientists and Social Care Staff can join.

For more information and to book:

https://www.eventbrite.co.uk/e/the-role-of-the-principal-investigator-pi-tickets-367530442447

External event organised by NIHR CRN Yorkshire & Humber

Posted 16/06/2022


Congratulation to Professor Hugh Jones

Congratulations to Prof. Hugh Jones, President of the Androgen Society, for being presented with the Grandmaster of Testosterone Award at the 2022 Annual Meeting of the Androgen Society. This award is in recognition of his continuing and progressive contributions to the study of testosterone and its treatment.

Prof Jones has been involved in research at Barnsley for a number of years and we wish him all the best.

Photo credit: https://www.androgensociety.org/ 

Posted 09/06/2022


What impact will COVID-19 have on our Mental Health?

A study BHNFT recruited over 450 participants to regarding the Psychological Impact of Covid-19, has an interesting article in the Spring 2022 edition of the NIHR Vision magazine.

Professor Shanaya Rathod talks about how we’re treating it now, the potential impact of long COVID and future ramifications. (page 23)

https://bit.ly/3rmPypZ

Also – Click the links below to see published papers working on the data generated.

World journal of psychiatry:

Journal of Affective Disorders

Posted 13/04/2022


NIHR Annual Report

The NIHR has published its latest Annual report highlighting its achievements during 2019/2020.

The report celebrates how NIHR funding and support continues to have a lasting impact on our health and social care system.

It details our world-class and ground-breaking research that is delivered by the talents and expertise within NIHR and the collaborations and partnerships we have forged. In addition to showcasing the breadth of areas NIHR provides funding and support, over 100 of our major research achievements are featured in the report, organised under the NIHR’s six core workstreams.

The report also gives an insight into the shifting focus to COVID-19 research as we came to the end of 2019/20.

Barnsley Hospital took part in COVID-19 research throughout this period, contributing to the RECOVERY study amongst others.

Further info :https://www.nihr.ac.uk/news/nihr-publishes-latest-annual-report/27175

Posted13/04/2022


The SIMS Trial

Single incision mini-slings for Stress Urinary incontinence in Women

SIMS results were recently published recently in the NEJM

click here for a study results infographic.

Posted 01/04/2022


RECOVERY Trial results

To date, the RECOVERY Trial has discovered three effective treatments for COVID-19:

  • the steroid dexamethasone
  • the arthritis treatment tocilizumab
  • and, a synthetic combination of monoclonal antibodies, now known as Ronapreve, that specifically target the coronavirus.

These results have changed clinical practice worldwide, helping to save countless lives.

 

The study has also proved that six treatments are not beneficial for patients hospitalised with COVID-19:

  • aspirin
  • azithromycin
  • colchicine
  • convalescent plasma
  • hydroxychloroquine
  • and lopinavir–ritonavir.

Many of these treatments were previously being used in some countries to treat COVID-19 patients.

 

These discoveries were only possible thanks to your hard work.

Together we have recruited nearly 45,000 participants in the UK, and provided reliable evidence about treatments for hospitalised patients.


Volunteers step up for Covid-19 Vaccine Study

Volunteers have been signing up at Barnsley Hospital for the latest COVID-19 Valneva vaccine study to be rolled out across the UK – with a local collaboration between Barnsley and Rotherham hospitals.

More than 100 local volunteers have responded to the study with the first cohort being vaccinated at a temporary ‘hub’ at Barnsley run and co-ordinated by NHS staff and hospital volunteers.

Jan Micallef, Research & Development Project Manager, said: “We have had an excellent response from volunteers especially as we had only a short time to recruit them. The Research & Development Team have been amazing in contacting local businesses and organisations to spread the word, and the people of South Yorkshire, particularly Barnsley and Rotherham have proved to be very altruistic in stepping up for the study to help research. Our hospital volunteers have also been great in assisting in the hub.”

4,000 participants are being recruited across the UK, and everyone involved in the study will receive two active vaccine doses, administered in a four-week interval. Those enrolled in the study over the age of 30 will be randomised to receive two doses of either the Valneva vaccine, or the approved Oxford/AstraZeneca vaccine. Participants have a preliminary screening online and from that go through to the next stage.

Jan added that the volunteers will be followed up for a year with seven appointments to check on their progress. Among the first volunteers in Barnsley were Chris Turner, 50, from Dinnington, and Kat Harbourne, 36, from Rotherham. Chris, who works for Sheffield City Council, said: “I’d not had a call-up for the standard vaccines – I think it may have been because I’d moved house – and I found out through Rotherham Hospital that they were looking for volunteers for this study. The hub here at Barnsley is well organised and if it helps to get another vaccine approved, that is great.”

Kat, who works at BBC Radio Sheffield, said: “My mum had Huntington’s Disease and had so much support from the NHS so I thought it would be good to give something back. I like the idea of helping other people.”

The National Institute for Health Research (NIHR)-supported Valneva Phase 2/3 study is open to healthy adults who have not had a previous COVID-19 vaccine.
Developed by Global biotech company Valneva, the vaccine is being manufactured at the company’s site in Livingston, West Lothian, and is the only inactivated, adjuvanted (an ingredient to create a stronger immune response) COVID-19 vaccine in clinical development in Europe.
Subject to successful Phase 2/3 data, Valneva aims to make regulatory submissions for initial approval in the autumn of 2021. If Valneva’s vaccine is shown to be effective, up to 250 million vaccine doses could be supplied to the UK and other countries around the world. As part of the UK government’s vaccine procurement approach, up to 100 million doses of this vaccine have been secured.

Find out more by visiting the Valneva study website – https://www.ukcovid19study.com/.

To register interest in vaccine studies and sign up to be contacted by researchers, people can visit the NHS COVID-19 Vaccine Research Registry (http://www.nhs.uk/researchcontact).

 

Volunteering for COVID-19 vaccine clinical trials:

People wishing to volunteer to support clinical trials can sign up for information on Covid-19 vaccine trials with the NHS Covid-19 Vaccine Research Registry, developed in partnership with NHS Digital. It is helping large numbers of people to be recruited into trials rapidly over the coming months – potentially meaning effective vaccines for coronavirus can be found as soon as possible. The service was commissioned as part of the UK Government’s Vaccine Taskforce in conjunction with the National Institute for Health Research (NIHR) and the Northern Ireland, Scottish and Welsh Governments. Anyone living in the UK can sign up online to take part in the trials through the NHS, giving permission for researchers to contact you if they think you’re a good fit. Once you sign up, you can withdraw at any time and request that your details be removed from the COVID-19 Vaccine Research Registry. The process takes about 5 minutes to complete .More information can be found: NHS.UK/coronavirus